Axio BioPharma and Likarda, a company focused on advanced drug delivery and formulation technologies, announced today a strategic partnership to accelerate innovation in biologic drug development.

According to a release, the collaboration will integrate Likarda’s proprietary delivery technologies with Axio’s manufacturing capabilities, creating a more efficient and scalable path to clinical manufacturing for clients across the biopharmaceutical sector.

“This partnership brings delivery innovation directly into the development process, helping our clients move faster and make better decisions,” Axio BioPharma CEO Justin Byers said in a statement. “By aligning earlier on both delivery and manufacturing, we reduce friction, shorten timelines and provide integrated solutions that truly support our clients’ goals.”

In addition, Likarda, which is based in Kansas City, Mo., will offer Axio’s discovery-to-GMP manufacturing capabilities to its client base.